Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

  title={Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs},
  author={Rickard E. Malmstr{\"o}m and Brian B Godman and Eduard Di{\`o}gene and Christoph Baumg{\"a}rtel and Marion Bennie and Iain Bishop and Anna Joanna Brzezińska and Anna E. Bucsics and Stephen Campbell and Alessandra Ferrario and Alexander Finlayson and Jurij F{\"u}rst and Kristina Garuolienė and Miguel Gomes and I{\~n}aki Guti{\'e}rrez-Ibarluzea and Alan Haycox and Krystyna Hviding and Harald Herholz and Mikael Hoffmann and Saira Jan and Jan W Jones and Roberta Joppi and Marija Kalaba and Christina Kvalheim and Ott Laius and Irene Langner and Julie Lonsdale and Sven-{\"A}ke L{\"o}{\"o}v and Kamila Malinowska and Laura McCullagh and Kenneth R Paterson and Vanda Markovi{\'c}-Pekovi{\'c} and Andrew Martin and Jutta Piessnegger and Gisbert Selke and Catherine Sermet and Steven Simoens and Cankat F. Tulunay and Dominik Tomek and Luka Von{\vc}ina and Vera V. Vlahovi{\'c}-Pal{\vc}evski and Janet L. Wale and Michael Wilcock and Magdalena Wladysiuk and Menno van Woerkom and Corrine Zara and Lars L. Gustafsson},
  booktitle={Front. Pharmacol.},
BACKGROUND There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 3 times. VIEW TWEETS


Publications citing this paper.
Showing 1-10 of 37 extracted citations

Similar Papers

Loading similar papers…